In a major departure from the normal urine collection for pregnancy detection, an Israeli company has introduced a saliva-based pregnancy test kit to reinforce the in-home testing experience.

Israeli startup Salignostics is answerable for developing the kit–Salistick–which might be available for purchase in various European countries, South Africa, the United Arab Emirates, and Israel. It’s also currently undergoing a certification process to expand its outreach.

Salistick is a user-friendly progressive approach that gives highly accurate results, particularly through the early stages of pregnancy. It may possibly be easily used anytime and in every single place, Abingdon, the only real distributor of Salistick within the U.K. said on its website.

Salistick detects pregnancy by identifying a hormone called human chorionic gonadotropin (hCG), which is made within the body when someone is pregnant. It’s accurate about 96.32% on the primary day after a missed period, and 97.35% on the second day, in accordance with IFL Science.

The creators of Salistick got here up with the thought after years of studying saliva. They realized that saliva might be used to detect several changes the body is undergoing, be it pregnancy or COVID-19. The researchers desired to make it easier for people to check for these conditions by utilizing saliva as an alternative of other methods like urine or blood, Wired reported back in 2022.

“Saliva is the important thing to rapid diagnostics for quite a lot of medical reasons. It’s the only non-invasive, easy, and hygienic means to detect hormones, viruses, and even diseases,” said Prof. Aaron Palmon, co-founder of Salignostics, told Wired. “With Salistick, we leverage the powerful diagnostics abilities now we have been capable of create from analyzing saliva. This product completely removes the necessity for blood and urine samples when testing for pregnancy.”

“This exciting innovation offers women the chance to check for pregnancy in a cleaner, more straightforward and easier way, and is a protracted overdue development within the pregnancy testing market,” said Chris Yates, CEO of Abingdon Health plc, in an announcement earlier this yr.

Published by Medicaldaily.com